At this meeting, EMDAC was asked to review the data from SAVOR, a large, randomized, double-blind, placebo-controlled postmarketing study designed to evaluate the cardiovascular effects of ONGLYZA.
Yesterday, the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 13 to 1 (with 1 abstention) that the results of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) study demonstrated that the use of saxagliptin in patients with type 2 diabetes has an acceptable cardiovascular risk profile. In addition, the majority of EMDAC members recommended that the product labeling be supplemented with new safety information, while one member voted to withdraw saxagliptin from the market. The materials for this meeting can be found HERE.
At this meeting, EMDAC was asked to review the data from SAVOR, a large, randomized, double-blind, placebo-controlled postmarketing study designed to evaluate the cardiovascular effects of ONGLYZA when added to current type 2 diabetes background therapy in adult patients with type 2 diabetes mellitus at risk for cardiovascular disease. Diabetes is estimated to affect 29.1 million people in the US and more than 382 million people around the world. Type 2 diabetes accounts for 90-95% of all diagnosed diabetes cases, and is a chronic disease characterized by pathophysiologic defects leading to elevated glucose levels.
ONGLYZA (saxagliptin) and KOMBIGLYZE XR (saxagliptin and metformin HCl extended-release) belong to a class of dipeptidyl peptidase-4 (DDP-4) inhibitors. DPP-4 inhibitors work by increasing the activity of incretin hormones or hormones that decrease elevated blood sugar levels. In addition to increasing incretin hormone activity, DDP-4 inhibitors increase the release of insulin when glucose levels are elevated and reduce the levels of sugar produced by the liver. Results of SAVOR showed that the primary safety objective was met, meaning ONGLYZA did not increase the risk for cardiovascular death, nonfatal myocardial infarction and nonfatal ischemic stroke when added to a patient’s current standard of care (with or without other antidiabetic therapy) as compared to placebo. The previously submitted supplemental New Drug Applications (sNDAs) based on the SAVOR results will provide prescribers and patients important additional information about the benefit-risk profile of ONGLYZA and KOMBIGLYZE XR, if approved.
The FDA is not bound by the Advisory Committee’s recommendation but often follows their advice.
ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComs per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact firstname.lastname@example.org.
Do you have an upcoming Advisory Committee Meeting?
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us